HCAT Form 144: Proposed Sale of 3,360 Shares ($11,299) on 09/02/2025
Health Catalyst, Inc. (HCAT) reported a Form 144 notice showing a proposed sale of 3,360 common shares through Morgan Stanley Smith Barney on 09/02/2025 with an aggregate market value of $11,298.67.
Rhea-AI Filing Summary
Health Catalyst, Inc. (HCAT) reported a Form 144 notice showing a proposed sale of 3,360 common shares through Morgan Stanley Smith Barney on 09/02/2025 with an aggregate market value of $11,298.67. The shares were acquired the same day as restricted stock issued by Health Catalyst as compensation. The filing lists 70,373,625 shares outstanding and indicates no securities sold by the reporting person in the past three months. The filer certifies no undisclosed material adverse information and provides standard Form 144 representations.
Positive
- None.
Negative
- None.
Insights
TL;DR Insider proposes to sell a small block of restricted shares acquired as compensation; size appears immaterial to capitalization.
The notice documents a proposed sale of 3,360 common shares valued at $11,298.67 executed via Morgan Stanley Smith Barney on 09/02/2025. These shares were acquired the same day as restricted stock issued by Health Catalyst and paid as compensation. Relative to the reported 70,373,625 shares outstanding, the block represents a negligible fraction of outstanding equity, suggesting limited market or governance impact. The filing confirms no sales in the prior three months and includes the standard attestation regarding material nonpublic information. From a compliance and disclosure perspective, the Form 144 appears routine and complete based on the provided fields.
TL;DR Routine disclosure of an insider sale tied to compensation; no red flags in the provided information.
The filing shows acquisition as restricted stock and subsequent proposed sale, a common sequence for awards subject to Rule 144 conditions. The inclusion of broker details and the attestation about material information align with regulatory expectations. Because the position size is minimal relative to total shares outstanding and there are no prior recent sales reported, this notice is unlikely to raise governance or signaling concerns based on the disclosed data alone.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Health Catalyst's Form 144 for HCAT disclose?
Does the Form 144 show recent sales by the reporting person?
Who is the broker handling the proposed HCAT sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.